4901 On Other Exchanges
Symbol
Exchange
4901 is not on other exchanges.

fujifilm holdings corp (4901) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FUJIFILM HOLDINGS CORP (4901)

fujifilm holdings corp (4901) Related Bloomberg News

View More Bloomberg News

fujifilm holdings corp (4901) Related Businessweek News

View More BusinessWeek News

fujifilm holdings corp (4901) Details

FUJIFILM Holdings Corporation develops, produces, sells, and services imaging, information, and document solutions worldwide. It operates through three segments: Imaging Solutions, Information Solutions, and Document Solutions. The Imaging Solutions segment offers color films, digital cameras, optical devices, color paper, services and equipment for photofinishing, instant photo systems, etc. The Information Solutions segment provides medical systems, life sciences products, pharmaceuticals, graphic arts, flat panel display materials, recording media, electronic materials, etc. The Document Solutions segment offers office copy machines/multifunction devices, printers, production systems and services, office services, papers, consumables, etc. The company was founded in 1934 and is headquartered in Tokyo, Japan.

78,150 Employees
Last Reported Date: 06/30/16
Founded in 1934

fujifilm holdings corp (4901) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: ¥207.0M
Chief Innovation Officer, Corporate Vice Pres...
Total Annual Compensation: ¥62.0M
Compensation as of Fiscal Year 2016.

fujifilm holdings corp (4901) Key Developments

Fujifilm Signs Patent License Agreement with Zhejiang Hisun Pharmaceutical

Fujifilm Holdings Corporation has signed a patent license agreement on its anti-influenza drug 'Avigan Tablet 200mg' with Zhejiang Hisun Pharmaceutical Co. Ltd. Under this agreement, Fujifilm grants Hisun Pharmaceutical a license to use its Favipiravir-related patents in China to develop, manufacture and market an anti-influenza drug in China. Fujifilm will receive a lump-sum payment and royalties once such an influenza drug is successfully introduced to the market. Avigan Tablet, created by the Fujifilm Group Company Toyama Chemical Co. Ltd., is an anti-influenza drug approved for manufacturing and marketing in Japan in March 2014. Influenza viruses replicate their genes within infected cells to propagate and release new viral particles and to spread the infection to other cells. Most existing anti-influenza drugs are Neuraminidase inhibitors, designed to block the release of propagated viral particles to prevent the spread of infection. In contrast, Avigan Tablet is a viral RNA polymerase inhibitor that blocks viral gene replication in cells thus preventing them from propagation. Due to this different mechanism of action, animal testing confirmed efficacy on a variety of avian influenza viruses. Hisun Pharmaceutical directed its attention to Avigan, which has manufacturing and marketing approval in Japan, to counter the growing concerns about a possible influenza pandemic in China. Anticipating Avigan's efficacy on Ebola virus and various other types of Negative-sense single strand RNA virus, which belong to the same category as influenza virus, the company approached Fujifilm last year to seek a patent license for the drug's effective ingredient, Favipiravir. China has had reports of humans infected with avian influenza (H5N1, H7N9, etc.) in addition to regular seasonal influenza. The need to develop new drugs for treating influenza has come amidst mounting concerns in recent years that avian influenza viruses could mutate into a new type of virus, capable of human-to-human transmission. Such a mutation could potentially trigger a pandemic. Fujifilm will continue to develop and supply innovative pharmaceutical products, resolving many of society's health challenges by combining the technologies and know-how accumulated in the photographic film business including chemical synthesis capacity, design ability, analysis technology and nanotechnology, with the technological expertise of its medical and pharmaceutical affiliates such as Toyama Chemical.

FUJIFILM Holdings Corporation, Board Meeting, Apr 27, 2016

FUJIFILM Holdings Corporation, Board Meeting, Apr 27, 2016. Agenda: To approve the stock acquisition rights.

Fujifilm Announces Water-Based Ink Development for Flexible Packaging at Drupa 2016

FUJIFILM Corporation will be exhibiting reference models of a pigment ink for water-based inkjet, to be used in flexible packaging, at drupa2016. Fujifilm is commercialising various inkjet related products under the "FUJIFILM Inkjet Technology" brand, a brand concentrating various Fujifilm technologies, and has introduced the B2 size digital press, the Jet Press 720S, originally made for commercial printing in the graphic arts industry. Additionally, the trend for short-runs, high-mix and quick turnarounds is ever-increasing in the packaging sector, and traditional analogue printing, the mainstream in the flexible package field, faces difficulties regarding turnaround, cost and environmental performance. This has led Fujifilm to further develop the technology used in the Jet Press 720S to create an ink technology for water-based inkjet capable of inkjet printing on flexible packaging film. The bleeding of inkjet ink is an issue in the non-absorbent film substrates used in the flexible packaging, but the application of "Rapic Technology" created during the development of the Jet Press 720S enables an ink droplet to retain its stability where it has landed, and clear image reproduction is made possible by combining with proprietary undercoating technology. The combination of these technologies with Fujifilm's high-definition Samba printheads has allowed productivity of more than 30 metres per minute to be achieved while printing at 1,200 dpi high-definition, in full color, enabling compatibility for digitalisation for the reverse printing of flexible packaging. A print sample of water-based ink will be exhibited at drupa in the "FUJIFILM Inkjet Technology" zone. An inkjet print sample of a shiny metallic ink currently under development will be exhibited as well. The development of metallic ink meets the increasing demand for indoor signs, packages and label printing with metallic textures to give a luxurious look. Other exhibits will include latest technologies in "inkjet printheads", "inks", "image optimization" and various samples showcasing the possibilities for expansion in the digital print market, including commercial printing, wide-format, package printing and numerous other fields in the industry.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4901 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4901.
View Industry Companies
 

Industry Analysis

4901

Industry Average

Valuation 4901 Industry Range
Price/Earnings 16.4x
Price/Sales 0.8x
Price/Book 0.9x
Price/Cash Flow 18.1x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact FUJIFILM HOLDINGS CORP, please visit www.fujifilmholdings.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.